South Dakota Investment Council Has $15.29 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

South Dakota Investment Council decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 37.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 136,411 shares of the biopharmaceutical company's stock after selling 80,827 shares during the period. South Dakota Investment Council's holdings in Gilead Sciences were worth $15,285,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Gilead Sciences during the first quarter worth about $25,000. Goodman Advisory Group LLC purchased a new stake in Gilead Sciences during the 1st quarter valued at about $29,000. Annis Gardner Whiting Capital Advisors LLC grew its stake in Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 216 shares in the last quarter. Core Alternative Capital grew its stake in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 241 shares in the last quarter. Finally, Lee Danner & Bass Inc. purchased a new stake in Gilead Sciences during the 4th quarter valued at about $41,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Down 0.5%

NASDAQ GILD traded down $0.58 during trading hours on Friday, reaching $108.22. 6,627,889 shares of the company traded hands, compared to its average volume of 7,673,118. Gilead Sciences, Inc. has a 12 month low of $70.78 and a 12 month high of $119.96. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The stock has a market capitalization of $134.62 billion, a PE ratio of 22.78, a PEG ratio of 0.70 and a beta of 0.29. The company has a 50 day moving average of $108.81 and a two-hundred day moving average of $105.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same period last year, the firm posted ($1.32) EPS. The company's revenue for the quarter was down .3% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.92%. Gilead Sciences's dividend payout ratio is presently 66.53%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on GILD shares. Morgan Stanley increased their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target for the company. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Oppenheimer dropped their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Finally, JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Nine equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus target price of $111.38.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the transaction, the director owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the transaction, the chief financial officer directly owned 162,610 shares in the company, valued at $18,054,588.30. This represents a 1.51% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 72,000 shares of company stock valued at $7,844,775. 0.27% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.